Cambridge Heartwear secures 184 million pound NHS wearable tender
Medical technology company Cambridge Heartwear secured a 184 million pound contract with the National Health Service to supply HeartSense a wirelessly charged electrocardiogram wearable
Cambridge Heartwear Limited has secured a £184 million contract with the National Health Service (NHS) for its groundbreaking HeartSense® wearable. The portable, wirelessly charged ECG device is the world's first medical-grade, multi-channel, AI-powered technology to deliver continuous heart monitoring straight to a patient's smartphone.
The agreement with the UK NHS Supply Chain will enable the deployment of HeartSense® across primary and secondary care, civil service departments, and homes. This empowers patients to monitor their heart rhythm at any time and location, enabling earlier detection of heart failure and stroke risk, reducing waiting times, and promoting preventative care.
HeartSense® combines diagnostic-grade multi-channel ECG monitoring, adaptive artificial intelligence, and wireless charging in a single, ergonomic-designed device. Engineered in Cambridge and manufactured in Britain, the technology has been developed to identify cardiovascular disease and stroke risk before conditions become acute. Its proprietary engineering and AI technology, protected by 86 patents, facilitate earlier intervention, allowing clinicians to make more informed decisions and improve patient outcomes.
The UKCA approved and ISO 13845 certified system is currently in the process of obtaining FDA 510(k) approval. Professor Rameen Shakur, the founder of Cambridge Heartwear, highlighted the significance of this partnership, stating, "We did not have a UK ECG manufacturer and reporter until now. HeartSense® is the world's first medical-grade, AI-powered, multi-channel ECG wearable, demonstrating what can be achieved when clinicians, engineers, and AI specialists collaborate."
The partnership with the NHS Supply Chain will allow Integrated Care Boards to scale the deployment of HeartSense®, supporting diagnostic-quality heart monitoring beyond hospital environments and reducing pressure on secondary care services. This initiative aims to improve access to high-quality cardiac diagnostics in community settings, ultimately reducing the burden of heart disease and enhancing patient care.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
